These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2574912)

  • 1. Effects of omeprazole on acid secretion and acid-related symptoms in patients with Zollinger-Ellison syndrome.
    Bardram L; Stadil F
    Scand J Gastroenterol Suppl; 1989; 166():95-100; discussion 111-3. PubMed ID: 2574912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety.
    Metz DC; Strader DB; Orbuch M; Koviack PD; Feigenbaum KM; Jensen RT
    Aliment Pharmacol Ther; 1993 Dec; 7(6):597-610. PubMed ID: 8161665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of acid suppressants in patients with Zollinger-Ellison syndrome.
    Maton PN
    Aliment Pharmacol Ther; 1991; 5 Suppl 1():25-35. PubMed ID: 1679671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers.
    Meijer JL; Jansen JB; Lamers CB
    Digestion; 1989; 44 Suppl 1():31-9. PubMed ID: 2575060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Maton PN; Gardner JD; Jensen RT
    Gastroenterol Clin North Am; 1989 Dec; 18(4):847-63. PubMed ID: 2575602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study.
    Maton PN; Vinayek R; Frucht H; McArthur KA; Miller LS; Saeed ZA; Gardner JD; Jensen RT
    Gastroenterology; 1989 Oct; 97(4):827-36. PubMed ID: 2777040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Present experiences with omeprazole in the Zollinger-Ellison syndrome.
    Lamers CB
    Scand J Gastroenterol Suppl; 1986; 118():123-8. PubMed ID: 3460167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists.
    Delchier JC; Soule JC; Mignon M; Goldfain D; Cortot A; Travers B; Isal JP; Bader JP
    Dig Dis Sci; 1986 Jul; 31(7):693-9. PubMed ID: 2873001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
    Hirschowitz BI; Mohnen J; Shaw S
    Aliment Pharmacol Ther; 1996 Aug; 10(4):497-506. PubMed ID: 8853753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome.
    McArthur KE; Collen MJ; Maton PN; Cherner JA; Howard JM; Ciarleglio CA; Cornelius MJ; Jensen RT; Gardner JD
    Gastroenterology; 1985 Apr; 88(4):939-44. PubMed ID: 3972233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Famotidine: effective treatment of Zollinger-Ellison syndrome.
    Howard JM; Vinayek R; Maton PN; Wank SA; Gardner JD; Jensen RT
    J Clin Gastroenterol; 1987; 9 Suppl 2():23-5. PubMed ID: 2887615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.
    Lambers CB; Lind T; Moberg S; Jansen JB; Olbe L
    N Engl J Med; 1984 Mar; 310(12):758-61. PubMed ID: 6142418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Vinayek R; Hahne WF; Euler AR; Norton JA; Jensen RT
    Dig Dis Sci; 1993 Oct; 38(10):1857-65. PubMed ID: 8104773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Famotidine in the therapy of gastric hypersecretory states.
    Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
    Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients.
    Corleto V; Annibale B; D'Ambra G; Saggioro A; Ferrua B; Cassetta MR; Delle Fave G
    Aliment Pharmacol Ther; 1993 Apr; 7(2):167-73. PubMed ID: 8485270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
    Howard JM; Chremos AN; Collen MJ; McArthur KE; Cherner JA; Maton PN; Ciarleglio CA; Cornelius MJ; Gardner JD; Jensen RT
    Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy.
    Stewart CA; Termanini B; Sutliff VE; Serrano J; Yu F; Gibril F; Jensen RT
    Aliment Pharmacol Ther; 1998 Jan; 12(1):83-98. PubMed ID: 9692706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.
    Pisegna JR; Norton JA; Slimak GG; Metz DC; Maton PN; Gardner JD; Jensen RT
    Gastroenterology; 1992 Mar; 102(3):767-78. PubMed ID: 1537514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: the management of Zollinger-Ellison syndrome.
    Maton PN
    Aliment Pharmacol Ther; 1993 Oct; 7(5):467-75. PubMed ID: 7904187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.